Fast Five Quiz: Exudative (Wet) Age-Related Macular Degeneration (AMD)

F. Ryan Prall, MD


March 31, 2022

Anti-VEGF agents are considered to have equivalent efficacy and safety profiles in AMD treatment. These agents have demonstrated improved visual and anatomic outcomes compared with other therapies. However, consensus has not been reached regarding the ideal treatment intervals with anti-VEGF agents.

On January 28, 2022, the FDA approved the first bispecific ophthalmologic antibody, faricimab, for the treatment of AMD. Recent studies have shown that faricimab may potentially extend the interval time between treatments.

Learn more about the use of antiangiogenic agents for management of wet AMD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.